Fluticasone furoate

Fluticasone furoate

Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	C for Intranasal
Routes of administration	Intranasal
ATC code	R01AD12 (WHO) R03BA09 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	0.51% (Intranasal)
Protein binding	91%
Metabolism	Intranasal Hepatic (CYP3A4-mediated)
Biological half-life	10 hours
Excretion	Renal
Identifiers
IUPAC name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
CAS Number	80474-14-2
PubChem CID	9854489
DrugBank	DB00588
ChemSpider	8030195
UNII	JS86977WNV
ChEBI	CHEBI:74899
ChEMBL	CHEMBL1676
ECHA InfoCard	100.158.130
Chemical and physical data
Formula	C27H29F3O6S
Molar mass	538.576 g/mol
3D model (Jmol)	Interactive image
SMILES C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
InChI InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1 Key:XTULMSXFIHGYFS-VLSRWLAYSA-N

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst and Flonase Sensimist (US), Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, and South Korea) for the treatment of allergic rhinitis administered by a nasal spray.

The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK), is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. As of 2015, it is also approved for the treatment of asthma.